Quantum BioPharma Announces Corporate Updates
Toronto, Ontario--(Newsfile Corp. - September 26, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces the following corporate
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-09-26 8:00 PM EDT | Quantum BioPharma Ltd.
Neural's Partner Hanf.com Expands Retail Footprint with 17th Store Opening Near Munich
Toronto, Ontario--(Newsfile Corp. - September 23, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for substance use disorders, together with CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CBD retailers, is pleased to announce the opening of its 17t
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-09-23 12:16 PM EDT | Neural Therapeutics Inc.
Optimind Pharma Announces Definitive Agreement for Proposed Change of Business with InterviewDesk
Toronto, Ontario--(Newsfile Corp. - September 8, 2025) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") is pleased to announce that it has entered into a binding definitive share exchange agreement dated September 5, 2025 (the "SEA") with IDesk Technologies Private Limited ("InterviewDesk"), a private company incorporated under laws of India, and its principal shareholders in respect of an arm's length transaction (the "Transaction") whi
Biotechnology, Cannabis, Health, Psychedelics
2025-09-08 3:18 PM EDT | Optimind Pharma Corp.
Optimi Announces Public Filing of Registration Statement for Proposed U.S. Initial Public Offering
Vancouver, British Columbia--(Newsfile Corp. - September 8, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company") a Canadian drug manufacturer of MDMA and naturally-derived psilocybin announces that it has publicly filed a registration statement with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed initial public offering of its common shares in the United States. The number of common share
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-09-08 7:00 AM EDT | Optimi Health Corp.
Optimind Pharma Announces Termination of Letter of Intent
Toronto, Ontario--(Newsfile Corp. - September 4, 2025) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") announces that its previously announced non-binding letter of intent dated March 18, 2025 with Monjin Interviews Private Limited ("Monjin"), with respect to the Company's acquisition of Monjin, has been mutually terminated by the parties. The Company is continuing to evaluate and review alternative acquisition opportunities. About the
Biotechnology, Cannabis, Health, Psychedelics
2025-09-04 4:00 PM EDT | Optimind Pharma Corp.
Red Light Holland's Wholly Owned Subsidiary Happy Caps Mushroom Farm Secures Continued Safeway Partnership to 123 Stores Across Two Seasonal Programs in the U.S.
Toronto, Ontario--(Newsfile Corp. - September 4, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe, is pleased to announce its secured an expansion milestone for its wholly owned subsidiary, 4316747 Nova Scotia Limited o/a Happy Caps Mushroom Farms ("Happy Caps") with Albertsons Companies and it's Safew
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2025-09-04 8:01 AM EDT | Red Light Holland Corp.